Vivid Genomics is at the forefront of advancing precision medicine in the field of neurodegenerative diseases, particularly Alzheimer's disease. The company has developed innovative tools to address the significant patient variability that complicates clinical trial outcomes. Their flagship technology, the Genomic Biopsy™, utilizes machine learning and genomics to create blood-based genetic tests that help pharmaceutical companies select and stratify patients for clinical trials. This approach aims to enhance the likelihood of trial success and drug approval by ensuring that the right patients are enrolled based on their genetic profiles and disease characteristics.

The company offers two primary tests: AmyloidGB™ and ProgressionGB™. AmyloidGB™ is designed to predict the presence of amyloid plaques, a key indicator of Alzheimer's disease, thereby enriching the patient population for clinical trials. ProgressionGB™, on the other hand, provides insights into the predicted rate of disease progression, which can be crucial for balancing trial arms and assessing the potential success of a trial retrospectively. By leveraging large neurogenetic datasets and sophisticated AI tools, Vivid Genomics is pioneering a new era of targeted therapies in dementia drug development, aiming to overcome the historical challenges faced in this domain.

United States

Vivid Genomics enables pharma companies to select and stratify the right patients for their clinical trials, increasing the probability of trial success and getting to an approved drug. We use machine learning and genomics to develop blood-based, genetic tests (“Genomic BiopsyTM”) for neurodegenerative diseases, beginning with Alzheimer’s.

Vivid Genomics

Company Details